CenterWatch Logo Welcome to the Malecare, Inc. Clinical Trials Resource Center, presented in partnership with CenterWatch, the leading publisher of information on clinical research for patients and their advocates and healthcare professionals. Please click on the links below to learn more about clinical research and new medical therapies for treating oncology-related conditions.

About Clinical Research
This section provides background information about the clinical trials process and what to expect when you volunteer to participate in a clinical trial. Here, you'll find answers to frequently asked questions about clinical trials and also suggestions for where to find more information.

FDA Approved Drugs » 1999
Medical Areas: Endocrinology | Oncology | Otolaryngology (Ear, Nose, Throat)

View By:Year | Company | Conditions | Therapeutic Areas | Drug Names

Ethyol (amifostine)

The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.

Company: US Bioscience, Alza
Approval Status: Approved June 1999
Treatment Area: Oncology

General Information

Ethyol has been approved to reduce xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer, where the radiation port includes a substantial portion of the parotid glands. Xerostomia--a chronic dry mouth condition--is a severe and often irreversible side effect of radiation therapy caused by damage to the salivary glands.

Side Effects

Side effects of Ethyol plus radiation in a Phase III study included nausea and vomiting which were sometimes severe. Side effects also included hypotension, fever, allergic-type skin reactions, dizziness/lightheadedness, fatigue/lethargy, rigors/chills, sneezing, sleepiness/somnolence, and flushing.